Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Hogan

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Blood|March 21, 2007
Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioningScott S Graves, William Hogan, Christian S Kuhr, et al.
Blood Cancer Journal|November 21, 2021
A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome predictionKalyan Nadiminti, Kimberly Langer, Ehsan Shabbir, et al.
American Journal of Hematology|August 25, 2020
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patientsErika Morsia, Kristen McCullough, Maansi Joshi, et al.
British Journal of Haematology|November 29, 2024
Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiMIuliana Vaxman, Shaji Kumar, Inbar Cohen, et al.
American Journal of Hematology|March 7, 2018
Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemiaJohn Ogden, Jennifer Yui, Walid Ali, et al.
Haematologica|March 2, 2023
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapyNaseema Gangat, Rimal Ilyas, Isla M Johnson, et al.
British Journal of Haematology|May 26, 2022
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experienceNaseema Gangat, Kristen McCullough, Aref Al-Kali, et al.
Bone Marrow Transplantation|December 4, 2020
Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agentsIuliana Vaxman, Alissa Visram, Shaji Kumar, et al.
Bone Marrow Transplantation|November 19, 2020
Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosisIuliana Vaxman, M Hasib Sidiqi, Abdullah S Al Saleh, et al.
Blood|May 22, 2012
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experienceAnita D'Souza, Martha Lacy, Morie Gertz, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Blood|March 21, 2007
Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioningScott S Graves, William Hogan, Christian S Kuhr, et al.
Blood Cancer Journal|November 21, 2021
A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome predictionKalyan Nadiminti, Kimberly Langer, Ehsan Shabbir, et al.
American Journal of Hematology|August 25, 2020
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patientsErika Morsia, Kristen McCullough, Maansi Joshi, et al.
British Journal of Haematology|November 29, 2024
Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiMIuliana Vaxman, Shaji Kumar, Inbar Cohen, et al.
American Journal of Hematology|March 7, 2018
Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemiaJohn Ogden, Jennifer Yui, Walid Ali, et al.
Haematologica|March 2, 2023
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapyNaseema Gangat, Rimal Ilyas, Isla M Johnson, et al.
British Journal of Haematology|May 26, 2022
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experienceNaseema Gangat, Kristen McCullough, Aref Al-Kali, et al.
Bone Marrow Transplantation|December 4, 2020
Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agentsIuliana Vaxman, Alissa Visram, Shaji Kumar, et al.
Bone Marrow Transplantation|November 19, 2020
Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosisIuliana Vaxman, M Hasib Sidiqi, Abdullah S Al Saleh, et al.
Blood|May 22, 2012
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experienceAnita D'Souza, Martha Lacy, Morie Gertz, et al.
Pageof 11